[What is happening with antiobesity drugs?].
Tinahones
Francisco José
FJ
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003131:Combined Modality Therapy; D019049:Developed Countries; D015195:Drug Design; D005062:European Union; D014943:Global Health; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced; D009765:Obesity / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration
D019440:Anti-Obesity Agents